Flavonoids, a prenatal prophylaxis via targeting JAK2/STAT3 signaling to oppose IL-6/MIA associated autism.
about
Atopic diseases and inflammation of the brain in the pathogenesis of autism spectrum disordersEffects of Flavonoids from Food and Dietary Supplements on Glial and Glioblastoma Multiforme CellsBrain "fog," inflammation and obesity: key aspects of neuropsychiatric disorders improved by luteolinNuclear termination of STAT3 signaling through SIPAR (STAT3-Interacting Protein As a Repressor)-dependent recruitment of T cell tyrosine phosphatase TC-PTPViral infection, inflammation and schizophreniaIntegrative analysis of genetic data sets reveals a shared innate immune component in autism spectrum disorder and its co-morbiditiesMaternal immune activation and autism spectrum disorder: interleukin-6 signaling as a key mechanistic pathwayThe viral theory of schizophrenia revisited: abnormal placental gene expression and structural changes with lack of evidence for H1N1 viral presence in placentae of infected mice or brains of exposed offspring.Neuro-inflammation, blood-brain barrier, seizures and autism.Effects of maternal immune activation on gene expression patterns in the fetal brainThe role of glycogen synthase kinase-3 signaling in neurodevelopment and fragile X syndromeAnimal models of autism: an epigenetic and environmental viewpoint.Possible involvement of the JAK/STAT signaling pathway in N-acetylcysteine-mediated antidepressant-like effectsThe role of nutraceuticals in the management of autismNeurotensin stimulates sortilin and mTOR in human microglia inhibitable by methoxyluteolin, a potential therapeutic target for autism.Potential Autoepitope within the Extracellular Region of Contactin-Associated Protein-like 2 in Mice.Knowledge-Guided Bioinformatics Model for Identifying Autism Spectrum Disorder Diagnostic MicroRNA Biomarkers.Anti-inflammatory effects of luteolin on experimental autoimmune thyroiditis in mice.Novel inhibitors of signal transducer and activator of transcription 3 signaling pathway: an update on the recent patent literature.Maternal immune activation and abnormal brain development across CNS disorders.Maternal immune activation dysregulation of the fetal brain transcriptome and relevance to the pathophysiology of autism spectrum disorder.Role of IL-6 in the etiology of hyperexcitable neuropsychiatric conditions: experimental evidence and therapeutic implications.Children with autism spectrum disorders, who improved with a luteolin-containing dietary formulation, show reduced serum levels of TNF and IL-6.Multiple pathways in prevention of immune-mediated brain disorders: Implications for the prevention of autism.Luteolin and thiosalicylate inhibit HgCl(2) and thimerosal-induced VEGF release from human mast cells.A case series of a luteolin formulation (NeuroProtek®) in children with autism spectrum disorders.Effects of a new nutraceutical substance on clinical and molecular parameters in patients with chronic venous ulceration.Microglia and Autism Spectrum Disorder: Overview of Current Evidence and Novel Immunomodulatory Treatment Options
P2860
Q26746354-8A4D2932-363B-47AE-82A0-0AF83FA928BDQ26778024-74F3FBDE-7971-4313-B92D-1588880A01B0Q26802187-E4D4E363-A12D-4486-9FD6-302BB95F1DDEQ28510611-756F3631-E69F-4F3C-B0B6-871A91612A56Q30440507-E82AF30B-C397-45E5-87A9-B0A56453235CQ31142266-BC870E45-AD8D-4083-8CC5-C21E07CFEFD6Q34141979-87965381-A216-4560-939B-E17C817CEF47Q35167037-A99CBB4D-4158-4937-9857-F51A8DAB3084Q35800334-AC311865-D21C-464F-A487-71EE98491298Q35913929-9EF0DC97-CF0A-49B4-802F-ACD5395FE5ABQ36304058-40DF88CB-7190-43B0-A367-AC1FF1E2ACE2Q36866412-474359F1-3F48-4AFD-8099-ADA65D063639Q37107518-315B8F46-E4DF-401A-8ECF-8750B988033BQ37246581-42F61AB1-74E2-4E38-91E0-A211EDCF8987Q37417949-BBEAE8CB-6801-4B53-8951-92FB393C3F4CQ37503310-FCB36F9F-134E-49E7-B43E-AB8047BAA762Q37522492-4F639326-602A-481A-ADA3-A7E4879D2058Q37582009-983875E6-EBE3-4041-8223-12D6235D3D14Q38179031-5DA283B6-F6C7-498D-B414-691E5A63ACBDQ38259759-466D8C48-6DAA-477C-8C4F-6FA1A01E5E60Q38404704-D0E88E72-C0C6-4263-A1F9-F481D711A634Q39512459-82B98C21-5E43-4AB8-9C5D-F4FC7BB84E4EQ41270272-3CC2740A-2F11-4227-B4B4-164201DF2476Q42696800-8E4370DD-F254-488F-BE74-3ED8520DA799Q42756906-E6F0C008-FD8F-4165-A279-312FF68EA606Q48474072-994BD8F5-E5DA-451C-8F96-5C4C1FBC1057Q48881971-6EEA596B-6ED6-4B9A-88C6-15928BF9F3ECQ58781425-3AAF38DE-C7A3-4165-8F10-57937F804D2E
P2860
Flavonoids, a prenatal prophylaxis via targeting JAK2/STAT3 signaling to oppose IL-6/MIA associated autism.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Flavonoids, a prenatal prophyl ...... se IL-6/MIA associated autism.
@en
Flavonoids, a prenatal prophyl ...... se IL-6/MIA associated autism.
@nl
type
label
Flavonoids, a prenatal prophyl ...... se IL-6/MIA associated autism.
@en
Flavonoids, a prenatal prophyl ...... se IL-6/MIA associated autism.
@nl
prefLabel
Flavonoids, a prenatal prophyl ...... se IL-6/MIA associated autism.
@en
Flavonoids, a prenatal prophyl ...... se IL-6/MIA associated autism.
@nl
P2093
P2860
P1476
Flavonoids, a prenatal prophyl ...... se IL-6/MIA associated autism.
@en
P2093
Antoinette Bailey
Brian Giunta
Ellisa Parker-Athill
Gabor Legradi
R Douglas Shytle
Tanya Murphy
P2860
P356
10.1016/J.JNEUROIM.2009.08.012
P577
2009-09-18T00:00:00Z